Keywords
Clinical Treatment
Surgery
How to Cite
Abstract
Introduction: Hepatitis is an inflammation of the liver that can be caused by several factors, including viruses, alcohol, medications, autoimmune diseases and toxins. Therefore, the results of clinical and surgical interventions in patients with hepatitis are influenced by the severity of the infection and the response to treatment, making the continuous study of these interactions essential to improve the prognosis. Objective: To evaluate the deadlines and results of surgeries and clinical treatments for hepatitis. Methodology: The Cochrane, Scielo and Pubmed databases were used, searching for articles published in the year 2024, in Portuguese or English. Final Considerations: Surgical surgeries, such as resections and transplants, play a fundamental role in the treatment of serious complications, while advances in antiviral therapies and clinical monitoring are crucial for controlling chronic hepatitis. Therefore, an integrated approach to liver surgery and the clinical treatment of hepatitis is essential for the effective management of liver pathologies, offering patients alternatives that can significantly improve clinical results and quality of life.
References
AGARWAL, K. et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology, v. 81, n. 3, p. 404–414, 5 abr. 2024.
BUTI, M. et al. Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide. Journal of Hepatology, 1 jul. 2024.
FARAG, M. S. et al. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B. Journal of Viral Hepatitis, 19 jan. 2024.
GUPTA, M. et al. Perioperative outcomes after hepatectomy for hepatocellular carcinoma among patients with cirrhosis, fatty liver disease, and clinically normal livers. Surg Oncol, p. 102114–102114, 2024.
GUSTAVO MACEDO HADDAD et al. DIAGNOSTIC ACCURACY OF THE NON-INVASIVE MARKERS NFLS, NI-NASH-DS, AND FIB-4 FOR ASSESSMENT OF DIFFERENT ASPECTS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN INDIVIDUALS WITH OBESITY: CROSS-SECTIONAL STUDY. Arquivos de Gastroenterologia, v. 61, 1 jan. 2024.
HÅVARD MIDGARD et al. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clinical infectious diseases/Clinical infectious diseases (Online. University of Chicago. Press), v. 78, n. 3, p. 582–590, 22 nov. 2023.
HOU, J. et al. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients. Clinical and Molecular Hepatology, v. 30, n. 2, p. 191–205, 8 jan. 2024.
KAMAL, A. et al. Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial. Journal of Gastrointestinal Cancer, v. 55, n. 2, p. 913–923, 4 mar. 2024.
QIAN, J. et al. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients. Hepatology, 8 jul. 2024.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Isadora Dias Lopes Ferrari, Luciana Kuster David, Yhanne dos Santos Soares Salles, Anna Caroline Vantil Lucas